Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

191 - Vascular targeted photodynamic therapy for pancreatic ductal adenocarcinoma; a pre-clinical success

Date

05 Mar 2018

Session

Poster display

Presenters

Ruth Goldschmidt

Citation

Annals of Oncology (2018) 29 (suppl_3): iii10-iii34. 10.1093/annonc/mdy047

Authors

R. Goldschmidt1, N. Koudinova1, K. Sasson1, D. Preise1, L. Agemy1, V. Mohan2, F. Bochner2, I. Sagi2, M. Neeman2, A. Scherz1

Author affiliations

  • 1 Plant Sciences Department, Weizmann Institute of Science, 7610001 - Rehovot/IL
  • 2 Biological Regulation, Weizmann Institute of Science, 7610001 - Rehovot/IL
More

Resources

Abstract 191

Vascular targeted photodynamic therapy (VTP) is based on in-situ photosensitization of a circulating drug leading to intravascular reactive oxygen species (ROS) generation and the subsequent tumors’ blood vessel occlusion that lead to the tumor necrosis. We have developed a series of bacteriochlorophyll derivatives, among them WST11 (TOOKAD®-Soluble) a water-soluble agent that has just been granted approval by the European community (EMA) for the treatment of early/intermediate prostate cancer. Application to other cancers, specifically to pancreatic ductal adenocarcinoma (PDAC) is being evaluated and may require adjustments of the treatment conditions. The following work presents the first pre-clinical results using WST11-VTP to treat syngeneic PDAC in mice.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings